Ticker brief
IDYA IDEAYA BIOSCIENCES INC
Consumer, Non-cyclical · Biotechnology
last close
$34.71
1 day
-3.9%
14 days
-3.9%
mkt cap
$3.6B
signals 14d
8
authors 14d
4
crowd 14d
-0.0σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 170% | IV/HV 4.08× (as of 2026-04-10) |
| Skew — 25Δ RR 30d | -0.988 | 25Δ call IV − put IV |
| OI alarm | quiet | last alarm 2026-04-09 (z=6.6) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-16 · now +0.40 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Quantumup1 | C | +0.10 | 4 | +0.40 |
| @Biotech2k1 | A | +1.11 | 2 | +0.65 |
| @BiopharmIQ | B | · | 1 | +0.00 |
| @bioinvestor24 | A | -0.87 | 1 | -0.10 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @Quantumup1 | +0.40 | William Blair initiated IDEAYA at Outperform and expressed bullishness on darovasertib's launch prospects. | +5.7% | tweet ↗ |
| 2026-10-15 | @bioinvestor24 | -0.10 | Compares oncology response and toxicity data, praising VSTM efficacy while flagging vomiting and liver-enzyme risks. | +2.5% | tweet ↗ |
| 2026-10-14 | @Quantumup1 | +0.40 | Stifel maintains Buy on IDEAYA with a $48 target and models $1.42 billion of 2035 product revenue. | +2.5% | tweet ↗ |
| 2026-10-13 | @Quantumup1 | +0.40 | Stifel resumes IDYA coverage at Buy with a $48 target. | +1.3% | tweet ↗ |
| 2026-10-08 | @Biotech2k1 | +0.55 | Discloses a second wave of purchases across four biotech stocks. | -3.7% | tweet ↗ |
| 2026-10-07 | @BiopharmIQ | +0.00 | Lists October clinical-readout timing for multiple biotech companies without directional odds. | -4.3% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | +0.75 | Buying IDYA and waiting to establish a LABD position. — Discloses an IDYA buy and forward intent to enter LABD. | -4.3% | tweet ↗ |
| 2026-10-06 | @Quantumup1 | +0.40 | Cantor reiterates Overweight on IDYA and highlights forthcoming clinical updates and regulatory alignment. | -5.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.